See more : Ambu A/S (AMBU-B.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Salarius Pharmaceuticals, Inc. (SLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Salarius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Haydale Graphene Industries plc (HAYD.L) Income Statement Analysis – Financial Results
- Molecular Partners AG (MOLN.SW) Income Statement Analysis – Financial Results
- Mason Group Holdings Limited (0273.HK) Income Statement Analysis – Financial Results
- AVITA Medical, Inc. (AVH.AX) Income Statement Analysis – Financial Results
- Nine Energy Service, Inc. (NINE) Income Statement Analysis – Financial Results
Salarius Pharmaceuticals, Inc. (SLRX)
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 1.84M | 5.23M | 3.47M | 838.00K | 1.28M | 1.01M | 0.00 |
| Cost of Revenue | 10.05K | 6.68K | 19.18K | 6.91K | 4.02K | 431.00K | 507.00K | 663.00K | 49.88K |
| Gross Profit | -10.05K | -6.68K | 1.82M | 5.23M | 3.46M | 407.00K | 768.00K | 348.00K | -49.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 98.96% | 99.87% | 99.88% | 48.57% | 60.24% | 34.42% | 0.00% |
| Research & Development | 7.17K | 15.84M | 8.55M | 6.91M | 4.02M | 11.91M | 16.99M | 20.38M | 12.75M |
| General & Administrative | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 2.35M | 1.37M | 797.49K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.22M | 17.14M | 19.06M | 0.00 |
| SG&A | 5.72K | 7.14M | 6.10M | 6.11M | 7.71M | 10.57M | 18.50M | 19.86M | 16.46M |
| Other Expenses | 0.00 | 8.87M | -4.00 | -178.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.48M | 35.49M | 40.23M | 29.21M |
| Cost & Expenses | 12.89K | 22.98M | 14.65M | 12.84M | 11.73M | 22.91M | 36.00M | 40.90M | 29.21M |
| Interest Income | 352.25K | 218.73 | 0.00 | 0.00 | 15.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.05K | 6.68K | 19.18K | 18.06K | 16.93K | 16.95K | 324.55K | 277.23K | 49.88K |
| EBITDA | -12.88K | -31.60M | -12.75M | -7.33M | -6.92M | -22.07M | -34.11M | -39.89M | -29.09M |
| EBITDA Ratio | 0.00% | 0.00% | -698.70% | -149.97% | -272.69% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Operating Income | -12.89K | -31.84M | -12.81M | -7.79M | -9.58M | -22.07M | -34.73M | -39.89M | -29.21M |
| Operating Income Ratio | 0.00% | 0.00% | -696.27% | -148.78% | -276.37% | -2,634.13% | -2,723.61% | -3,945.20% | 0.00% |
| Total Other Income/Expenses | 352.25 | 233.18K | 44.69K | 434.09K | 1.33M | 152.01K | 291.96K | 393.11K | 72.00K |
| Income Before Tax | -12.54K | -31.61M | -12.77M | -7.35M | -6.94M | -21.92M | -34.43M | -39.49M | -29.14M |
| Income Before Tax Ratio | 0.00% | 0.00% | -693.84% | -140.49% | -200.23% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| Income Tax Expense | 0.00 | -233.18K | -63.88K | -255.50K | -1.33M | 152.01K | -324.58K | -277.12K | -49.85K |
| Net Income | -12.54K | -31.37M | -12.70M | -7.10M | -5.61M | -21.92M | -34.43M | -39.49M | -29.14M |
| Net Income Ratio | 0.00% | 0.00% | -690.37% | -135.61% | -161.88% | -2,615.99% | -2,700.71% | -3,906.33% | 0.00% |
| EPS | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| EPS Diluted | 0.00 | -14.77 | -7.68 | -11.39 | -42.90 | -760.47 | -1.25K | -1.52K | -1.30K |
| Weighted Avg Shares Out | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
| Weighted Avg Shares Out (Dil) | 3.26M | 2.12M | 1.65M | 623.14K | 130.75K | 28.83K | 27.62K | 25.97K | 22.45K |
Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option
HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the closing of its previously announced underwritten public...
Salarius Announces Proposed Public Offering of Common Stock
HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has commenced an underwritten public offering...
SLRX Stock Price Increases Over 20% Pre-Market: Why It Happened
The stock price of Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is trading at over 20% pre-market. This is why it happened.
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference
HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Salarius CEO David Arthur will present during...
Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients
Seclidemstat safety profile affirmed; Recommended Phase 2 dose established
Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it will participate in the BIO CEO & Investor...
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the...
Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference
HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharm aceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteban, Ph.D., Director of...
Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas
HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the receipt of a $0.9 million payment as...
Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"
HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that the company is participating in Biotech Showcase Digital and...
Source: https://incomestatements.info
Category: Stock Reports